Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine Plus Nab-Paclitaxel Following Induction With Sequential IV Gemcitabine Plus Nab-Paclitaxel and Radiotherapy for Locally Advanced Pancreatic Cancer

Next Previous
X
Search
Trial Profile

Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine Plus Nab-Paclitaxel Following Induction With Sequential IV Gemcitabine Plus Nab-Paclitaxel and Radiotherapy for Locally Advanced Pancreatic Cancer

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gemcitabine (Primary) ; Capecitabine; Gemcitabine; Paclitaxel
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms TIGeR-PaC
  • Sponsors RenovoRx

    • Most Recent Events

    • 27 Aug 2024 According to a RenovoRx media release, the second interim analysis for this study will be triggered by the 52nd event, which is estimated to occur in late 2024 or early 2025.
    • 27 Aug 2024 According to a RenovoRx media release, Mr. Bagai will discuss recent corporate achievements including progress on RenovoRx's pivotal ongoing Phase III TIGeR-PaC clinical trial at H.C. Wainwright's 26th Annual Global Investment Conference being held at the Lotte New York Palace Hotel in New York City.
    • 14 Aug 2024 According to RenovoRx media release, the first patient has been enrolled at the University of Nebraska Medical Center (UNMC). UNMC will help drive enrollment of the TIGeR-PaC trial to completion next year because they treat a larger number of patients diagnosed with pancreatic cancer.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top